AtriCure to Acquire nContact

Atrial fibrillation solutions provider AtriCure has reached an agreement to acquire nContact, a developer of cardiac ablation solutions.

The agreement consists of an upfront payment of approximately 3.7 million shares of AtriCure common stock, valued at $24.60 per share, and about $8 million in cash.

Atricure will expand its existing portfolio with the addition of nContact’s products for the treatment of cardiac arrhythmias.

The transaction is expected to close within the next several weeks. — Michael Cipriano